📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.
In 2025, Alembic Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Alembic Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Alembic Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
In 2025, the total operational greenhouse gas (GHG) emissions ofAlembic Pharmaceuticals amounted to158,244.01metric tons of CO2 equivalent.This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Alembic Pharmaceuticalsincreased by 14.11%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of Alembic Pharmaceuticals were 80,278.03 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a
Compared to the previous year(2024), Alembic Pharmaceuticals's Scope 1 emissions increased by 12.86%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2025, Alembic Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 77,965.98 tCOâ‚‚e without specifying the calculation method.a
Compared to the previous year(2024), Alembic Pharmaceuticals's Scope 2 emissions(Unspecified Calculation Method) rose by 15.43% in 2025, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2025, Alembic Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology.a
In 2025, Alembic Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 80,278.03 tCOâ‚‚e and total revenues of USD 765 millions. This translates into an emissions intensity of 104.88 tCOâ‚‚e per millions USD.a
In 2025, Alembic Pharmaceuticals reported a Scope 1 emissions intensity of 104.88 tCOâ‚‚e per millions USD. Compared to the peer group median of 22.24, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2025, Alembic Pharmaceuticals ranked 20 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCOâ‚‚e per millions USD).a
This places Alembic Pharmaceuticals among the least efficient performers, with one of the highest emissions intensities in its sector.a